Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin and Lilly release new diabetes medication
The drug, Byetta (exenatide) injection is now available for Americans struggling to control type 2 diabetes. Byetta was recently approved by the FDA to help diabetes patients manage
The drug, Byetta (exenatide) injection is now available for Americans struggling to control type 2 diabetes. Byetta was recently approved by the FDA to help diabetes patients manage
Amyloid A (AA) Amyloidosis is a rare disease that is a consequence of chronic inflammatory diseases like rheumatoid arthritis and familial Mediterranean fever and frequently progresses to end-stage
Tarvacin is a chimeric monoclonal antibody that binds directly to tumor blood vessels to inhibit growth and development of solid tumors. The drug has also shown promise in
The approval follows a positive opinion granted on April 21, 2005, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). Temodal
Abatacept is an investigational selective co-stimulation modulator, which, according to new findings from a recent phase III clinical trial, is affective against arthritus independent of baseline clinical, biochemical,
The final data from the phase I trial showed the drug candidate ISIS 301012 to be capable of producing rapid and prolonged reductions of its target, ApoB-100, with
Data from the trial, named ‘Adept’, showed that patients receiving Humira experienced an improvement in quality of life during a 24-week period. Following 24 weeks of treatment, 42%
The trial data indicated that at 18-23 months’ follow-up, there was symptomatic improvement and no safety problems in individuals treated with NX-1207. The symptomatic improvement was determined to
The company has also enrolled more than 300 patients who will receive active medication for six months in accordance with the International Conference on Harmonisation guidelines. Recruitment activities
A global study of nearly 5,000 people with poorly controlled type 2 diabetes demonstrated that treatment regimens that included the once-daily basal insulin Lantus significantly improved glycemic (blood